Antibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung Cancer
An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and a manageable safety profile in previously treated EGFR-mutated lung ...
Tag: Progression-Free Survival
Meningiomas with brain invasion alone show better survival than other grade 2 tumors
A newly published study from a team of neurosurgeons and neuropathologists is challenging a long-standing assumption in brain tumor classification, ...
Weekly Cladribine Plus Rituximab Shows Promise Against Hairy Cell Leukemia
A weekly dosing schedule for a decades-old leukemia drug appears to outperform the standard daily infusion regimen in hairy cell ...
ECOG-ACRIN ENDURANCE Trial Publishes Randomized Evidence on Lenalidomide Maintenance Duration in Multiple Myeloma
A landmark phase 3 trial in newly diagnosed multiple myeloma challenges a long-standing standard: indefinite lenalidomide maintenance. For patients who ...
CDK4/6 Inhibitors Boost First-Line Breast Cancer Therapy
In an ambitious stride toward optimizing treatment for hormone receptor-positive (HR+)/HER2-negative advanced breast cancer, a recent comprehensive network meta-analysis has ...
Exploring How Pomalidomide Enhances Immune Response in the Battle Against Multiple Myeloma
Pomalidomide (POM) has emerged as a pivotal agent in the treatment landscape for multiple myeloma, a malignancy that significantly compromises ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!